.avif)
.png)
A diagnostics company
Ten years ago, Rory built a diagnostics company on aptamers.
.avif)
.avif)
.avif)
%201.avif)
The Vision
Why we built PentaBind
Rory didn't start in aptamer design, he started as the customer they kept failing.
75- 100 days
from target to application-ready asset
300×
more high-affinity hits
10+ characteristics
modelled across data spanning 800+ proteins
A supply model that kept failing
Externally sourced aptamers often bound in buffer but failed under application-relevant conditions.
The exit
Rory spent six years building the company before successfully exiting.
.png)
An industry-wide problem
The bottleneck extended beyond one supplier or target. PentaBind was built to solve it systematically.
A perspective no one else in aptamers has.
Most suppliers have only ever worked in the lab. We've been the customer, the builder, and the operator.
In-buffer binder
Proof-of-concept or simple publication.
SenseReady
Commercially viable aptamer engineered since the beginning.
Built the hardware
Designed and shipped real diagnostic devices, not just molecules.
.avif)
Ran the supply chains
Built manufacturing and supply across Shenzhen and London.
.avif)
Lived the fundraise
Knows the technology and capital challenges partners face firsthand.
.avif)
Closed-loop AI + wet lab
A compounding data advantage competitors can't replicate.
Built for product development. Not just molecular discovery.
.avif)
.avif)
Leadership team.
Rory Ryan
CEO & Co-founder
Exited founder; decade of experience in aptamer commercialisation.
Dr. Miguel Gonzalez
CAIO & Co-founder
10+ years AI/HPC; builds AI–wet-lab engine.
Dr. Phil Haynes
CTO & Co-founder
10+ years DNA/drug interaction research.
Dr. Ban Balansethupathy
Chief Scientist Aptamer Solutions
Ex-Aptamer Group; leads wet-lab execution.
Dr. Yashas Kannan
VP Drug Discovery
Ex-GSK director, 12+ years in drug discovery strategy.
Trusted by FS500 and VC-backed scale-ups · backed by leading programs
